{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-23-000014","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.234072+00:00","generated_at":"2026-06-18T11:50:14.715402+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Krystal Biotech appoints Catherine Mazzacco to Board of Directors","bullets":["Board expanded from 8 to 9 directors; Catherine Mazzacco appointed as independent Class I director effective March 6, 2023.","Mazzacco will serve on the Nominating and Corporate Governance committee and stand for election at 2024 annual meeting.","She previously served as CEO & President of LEO Pharma and SVP at GE HealthCare, with 25+ years at Abbott Laboratories.","No material transactions or arrangements between Mazzacco and the company; standard director compensation applies."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-23-000014","json":"https://secwatch.observer/filing/0001711279-23-000014.json","markdown":"https://secwatch.observer/filing/0001711279-23-000014.md","text":"https://secwatch.observer/filing/0001711279-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000014/0001711279-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000014/krys-20230306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:50:14.715402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9595bb780","claim":"Catherine Mazzacco was appointed as independent member of the Board at Krystal Biotech, Inc..","evidence_excerpt":"On March 6, 2023, the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”) approved an increase in the size of the Board from eight (8) directors to nine (9) directors and appointed Catherine Mazzacco as an independent member of the Board to fill the vacancy created by the increase in the size of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000014/0001711279-23-000014-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"independent member of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}